Pharmaceutical giant AstraZeneca's agreement to sell much of its antibiotics business won't impact operations at MedImmune, its Gaithersburg-based research and development arm, officials confirmed Wednesday.
SUBSCRIBE
Biohealth Innovation
Founding Member of
